LAMB3 and junctional epidermolysis bullosa: Our research group further investigated the efficacy and safety of IV gentamicin in our open-label phase 1/2 clinical trial involving five pediatric JEB patients harboring nonsense mutations in LAMA3 or LAMB3 and decreased baseline expression of laminin-332 [46].